Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 17/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | FPR3 | P25089 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357338 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL14357339 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL5440516 | 0.91 | ADRB2 (0.55) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL5440507 | 0.91 | ADRB2 (0.55) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL2008580 | 0.90 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL2008579 | 0.90 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL2008582 | 0.90 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL5450624 | 0.90 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL5450633 | 0.90 | ADRB2 (0.61) | ADRB2ADRB1ADRB3CYP3A4KDM4E | |
| SCHEMBL5433683 | 0.90 | ADRB2 (0.45) | ADRB2ADRB1ADRB3CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7294725-B1 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294725-B1 | Process for preparing salmeterol | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| CN-1189446-C | 6- (4-phenylbutoxy) hexylamine derivative and method for obtaining salmeterol | VITA INVEST SA (ES) | 2005-02-16 | — | — | CN | disclosed |
| EP-1132373-B1 | NEW DERIVATIVES OF 6-(4-PHENYLBUTOXY)HEXYLAMINE AND PROCESS FOR PRODUCING SALMETEROL | VITA LAB (ES) | 2003-11-19 | — | — | EP | disclosed |
| US-6388134-B1 | CHEMICAL INTERMEDIATES | INKE, S.A. (ES) | 2002-05-14 | — | — | US | disclosed |
| CN-1320114-A | Novel 6- (4-phenylbutoxy) hexylamine derivative and method for obtaining salmeterol | VITA INVEST SA (ES) | 2001-10-31 | — | — | CN | disclosed |
| EP-1132373-A2 | NEW DERIVATIVES OF 6-(4-PHENYLBUTOXY)HEXYLAMINE AND PROCESS FOR PRODUCING SALMETEROL | VITA-INVEST, S.A. (ES) | 2001-09-12 | — | — | EP | disclosed |
| US-5243076-A | Adrenergic stimulant intermediates | GLAXO GROUP LTD. | 1993-09-07 | — | — | US | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 5/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.